![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Samsung Medical Center |
---|---|
Information provided by: | Samsung Medical Center |
ClinicalTrials.gov Identifier: | NCT00620646 |
To compare the effect of increased dosing of clopidogrel and adding cilostazol to standard dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel resistance
Condition | Intervention |
---|---|
Clopidogrel Non-Responsiveness |
Drug: aspirin, clopidogrel Drug: aspirin, clopidogrel, cilostazol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol in Clopidogrel Non-Responders After Drug-Eluting Stent Implantation |
Estimated Enrollment: | 80 |
Study Start Date: | February 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
Aspirin plus increasing clopidogrel group
|
Drug: aspirin, clopidogrel
aspirin 100 mg plus clopidogrel 150mg qd
|
B: Experimental
Aspirin, clopidogrel plus cilostazol group
|
Drug: aspirin, clopidogrel, cilostazol
aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
|
Using dual antiplatelet agents with aspirin and clopidogrel is essential after drug-eluting stent implantation to prevent restenosis and stent thrombosis. However, variable platelet response and potential resistance to therapy have emerged with clopidogrel. Several studies showed that clopidogrel resistance is associated with increased cardiovascular events after coronary interventions. New antiplatelet therapeutic strategy of is needed in case of clopidogrel resistance. We started this study to compare the effect of double dosing of clopidogrel to 150mg per day and adding cilostazol to standard dose of clopidogrel after the insertion of drug-eluting stent in patients with clopidogrel resistance.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Hyeon-Cheol Gwon, MD,PhD | 82-2-3410-3418 | hcgwon@smc.samsung.co.kr |
Contact: Joo-Yong Hahn, MD, PhD | 82-2-3410-3419 | jyhahn@medimail.co.kr |
Korea, Republic of | |
Samsung Medical Center | Recruiting |
Seoul, Korea, Republic of, 135-710 | |
Contact: Hyeon-Cheol Gwon, Professor 82234103419 hc.gwon@samsung.com |
Principal Investigator: | Hyeon-Cheol Gwon, MD, PhD | Samsung Medical Center |
Responsible Party: | Samsung Medical Center ( HC Gwon ) |
Study ID Numbers: | 2006-12-026-001 |
Study First Received: | January 27, 2008 |
Last Updated: | February 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00620646 |
Health Authority: | South Korea: Institutional Review Board |
clopidogrel platelets percutaneous coronary intervention |
Cilostazol Aspirin Clopidogrel |
Anti-Inflammatory Agents Respiratory System Agents Vasodilator Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hematologic Agents Fibrinolytic Agents Neuroprotective Agents Fibrin Modulating Agents Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Cyclooxygenase Inhibitors |
Anti-Asthmatic Agents Enzyme Inhibitors Cardiovascular Agents Protective Agents Pharmacologic Actions Phosphodiesterase Inhibitors Analgesics, Non-Narcotic Autonomic Agents Platelet Aggregation Inhibitors Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents Bronchodilator Agents |